Immunogenomic Correlates of Response to Cetuximab in Head and Neck Squamous Cell Carcinoma

Immune evasion is a sine qua non for cancer development. Mechanisms of resistance to immune modulating therapeutics in cancer are poorly understood. Less than 20% of patients with HNSCC have a lasting response to cetuximab. We hypothesized that acquired somatic alterations may provide a mechanism of immune evasion in cetuximab failure. Here, using a novel cohort of HNSCC patients treated with neoadjuvant cetuximab, we investigated mechanisms of immune escape from cetuximab therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research

Related Links:

Jo VY, Stachler MD, Hanna GJ, Kass JI, Haddad RI, Schoenfeld JD, Gjini E, Lako A, Thorstad WL, Gay HA, Daly M, Rodig S, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR Abstract PURPOSE: Pembrolizumab improved survival in recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC) patients. The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)-unrelated HNSCC. METHODS: Neoadjuvant pembrolizumab (200 mg) was administe...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionSquamous cell carcinoma (SCC) is the most common cancer occurring in the Head and Neck. Squamous cell carcinoma is also the most common cancer arising within the nose and sinuses of which skull-base squamous cell carcinoma is a rare subgroup.Evidence relating to the management and survival of skull-base SCC is based on expert opinion and. retrospective analyses Clinical examination and biopsy, imaging and a broad multidisciplinary team are key to the management of skull-base SCC. The information gathered should be used to guide informed discussion by suitably trained experts with patients regarding surgical appro...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: In OSCC, very low preoperative NLR values have a negative prognostic impact on survival and recurrence, similarly to high ratios. ENE and perineural spread are the most important clinical-pathologic prognosticators. Introduction Oral squamous cell carcinoma (OSCC) accounts for more than 95% of oral tumors and is the eighth most frequent cancer worldwide, with an estimated incidence of 640,000 new cases per year (1). Survival of OSCC has slightly improved over the last 30 years, probably as a consequence of multimodal treatment spreading. However, intensified therapeutic regimens can result in signific...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Fat fraction on MRI corresponded to fat content on histology and therefore contributes to lesion characterization. Measurement repeatability was excellent for ADC; this parameter increased significantly post-radiotherapy even in disease categorized as stable by size criteria, and corresponded to cellularity on histology. ADC can be utilized for characterizing and assessing response in heterogeneous retroperitoneal sarcomas. Introduction Soft-tissue sarcomas are often highly heterogeneous tumors with variable components that can include cellular tumor, fat, necrosis, and cystic change. In many soft-tissue ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions In the span of a very short time—less than a decade—robotic head and neck surgery has transformed the management of the head and neck cancer, and it seems clear that the future of treatment for these cancers lies in a multimodal approach in which TORS is likely to play an important role. Nevertheless, it is important to keep in mind that the current indications for TORS are limited and long-term data on the safety and oncological outcomes are needed to better understand the true role of TORS in treatment of head and neck cancer. Nonetheless, the emergence of ever more advanced robotic instruments i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Approximately 60% of head and neck squamous cell carcinoma (HNSCC) patients present with locally advanced disease. Surgical candidates often receive postoperative radiation and cisplatin if they have high-risk pathological features. Despite intensive therapy, up to 50% of patients will suffer relapse. Therefore, improved treatment modalities are desperately needed. The checkpoint inhibitor, programmed death-ligand 1 (PD-L1), is upregulated in HNSCC and treatment with anti-PD-1 inhibitor (pembrolizumab) was shown to decrease tumor burden in patients with recurrent/metastatic HNSCC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Palbociclib;   Drug: Cetuximab;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Tumor biopsy;   Procedure: Peripheral blood draw;   Other: European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Sponsors:   Washington University School of Medicine;   Pfizer Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Erbitux | Head and Neck Cancer | HNSCC | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Physics | Skin Cancer | Squamous Cell Carcinoma